Literature DB >> 12475654

Surgical management of the urinary tract in patients with locally advanced colorectal cancer.

Masato Fujisawa1, Takeshi Nakamura, Masakazu Ohno, Jiro Miyazaki, Soichi Arakawa, Takahiro Haraguchi, Nozomu Yamanaka, Akihisa Yao, Osamu Matsumoto, Yoshikazu Kuroda, Sadao Kamidono.   

Abstract

OBJECTIVES: To review cases of colorectal cancer requiring urologic management to clarify the role the urologist should play in the surgical procedures. A deterrent to radical surgery for advanced colorectal carcinoma with urinary involvement is the technical complexity and associated morbidity and mortality of this procedure.
METHODS: Thirty-six tumors in 35 patients, including 19 sigmoid cancers (Stage II, 17; Stage III, 2), 12 rectal cancers (Stage II, 11; Stage III, 1), and 5 local recurrences of colorectal carcinoma in the pelvis were reviewed. All tumors had invaded the bladder, prostate, or ureter. The demographic and clinical characteristics, type of operative procedure, and postoperative complications were analyzed.
RESULTS: Of the patients with a sigmoid tumor, partial cystectomy was performed in 15 patients who underwent a bladder-sparing procedure; an ileal conduit and ileal neobladder were created in 2 patients each who required cystectomy. Four patients with rectal cancer underwent a bladder-sparing procedure: partial cystectomy in 1, partial cystectomy with ileal ureter in 1, and prostatectomy in 2. The remaining 8 patients underwent cystectomy with the following types of reconstruction: colonic neobladder in 1, ileal neobladder in 4, Indiana pouch in 1, ileal conduit in 1, and ureterocutaneostomy in 1 patient. The bladder was spared in a greater percentage of patients with sigmoid cancer than in those with rectal cancer. The incidence of complications was greater in patients with rectal cancer and local recurrence than in those with sigmoid tumors. The complication rate was especially low in patients who underwent a bladder-sparing procedure (10.5%) compared with patients who required cystectomy (58.3%). The survival in patients with sigmoid cancer who underwent bladder-sparing surgery also was better than in those who underwent cystectomy.
CONCLUSIONS: The treatment of advanced colorectal cancer is best managed by a committed team that includes an experienced urologist. Urologists play a critical role in determining the surgical options and creating appropriate urinary diversions to achieve curative resection with the highest quality of life.

Entities:  

Mesh:

Year:  2002        PMID: 12475654     DOI: 10.1016/s0090-4295(02)01987-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Total pelvic exenteration for rectal cancer: outcomes and prognostic factors.

Authors:  Trustin S Domes; Patrick H D Colquhoun; Brian Taylor; Jonathan I Izawa; Andrew A House; Patrick P W Luke; Jonathan I Izawa
Journal:  Can J Surg       Date:  2011-12       Impact factor: 2.089

2.  The double-barreled wet ileostomy: an alternative method for simultaneous urinary and intestinal diversion without intestinal anastomosis after total colectomy and pelvic exenteration.

Authors:  Gustavo Cardoso Guimarães; Fabio Terabe; Benedito Mauro Rossi; Samuel Aguiar Júnior; Fabio de Oliveira Ferreira; Wilson Toshihiko Nakagawa; Ademar Lopes
Journal:  Int J Colorectal Dis       Date:  2004-10-15       Impact factor: 2.571

3.  Outcome of surgical management of the bladder in advanced colorectal cancer.

Authors:  Feng Gao; Yun-fei Cao; Li-sheng Chen; Sen Zhang; Zong-jiang Tang; Jun-lin Liang
Journal:  Int J Colorectal Dis       Date:  2006-03-01       Impact factor: 2.571

4.  [Cystectomy for indications other than bladder cancer].

Authors:  S Hautmann; K-H Felix-Chun; E Currlin; M G Friedrich; J Dose Schwarz; T Langwieler; S Conrad; H Huland
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

Review 5.  Clinical review: surgical management of locally advanced and recurrent colorectal cancer.

Authors:  D Courtney; F McDermott; A Heeney; D C Winter
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.